Merck will slash about 500 jobs in early 2020 at two Montgomery County, Pa., facilities as well as in some other states, Pennsylvania’s Morning Call reported.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
J&J’s Janssen Pharmaceutical released new long-term data from the open-label period of the Phase III VOYAGE 1 study.
The U.S. drug regulator will give a speedy review to AstraZeneca Plc’s experimental breast cancer treatment trastuzumab deruxtecan.
Yale University researchers developed a new system dubbed Multiplexed Activation of Endogenous Genes as Immunotherapy (MAEGI) that hunts down cancer cells.
The U.S. FDA approved Janssen’s Xarelto (rivaroxaban) for preventing blood clots in acutely sick patients in hospitals who are at risk for blood clots but who are not at high risk of bleeding.
AbbVie Inc.’s rheumatoid arthritis drug Humira and Roche Holding AG’s cancer drug Rituxan topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report showed.
While the top-selling prescription drug Humira is on the decline internationally due to increased competition and expiring patents, another medicine is on track to eventually take hold of the world’s No. 1 rank: Merck’s Keytruda.
AstraZeneca presented results for a late-stage clinical trial of Lynparza against prostate cancer, which the company hopes could lead to wider regulatory approval for more forms of the disease.
Novartis said Kisqali helped women with advanced breast cancer after menopause live longer, adding to data the Swiss company hopes will help convince doctors to choose the drug over Pfizer’s blockbuster Ibrance.
Positive Data Reported for Merck’s Keytruda Plus Chemo Combo as Neoadjuvant Therapy in Early-Stage TNBC
Merck announced results from the pivotal neoadjuvant/adjuvant Phase 3 KEYNOTE-522 trial in patients with early-stage triple-negative breast cancer (TNBC).